Tenofovir Disoproxil Fumarate: In Vitro SARS-CoV-2 Activity and Chemical Degradation Data

A short report by Giuliano C. Clososki presents new chemical developments and in vitro biological results for the antiretroviral Tenofovir disoproxil fumarate (TDF) against SARS-CoV-2. The work includes a scale-up investigation monitored by in situ infrared spectroscopy and a forced degradation study identifying a new degradation product. This represents the first in vitro evaluation of TDF for SARS-CoV-2, suggesting its potential for pre-clinical and clinical COVID-19 investigations.

Use Cases

• Assessing drug repurposing candidates for SARS-CoV-2 based on in vitro biological results mentioned in the description
• Analyzing chemical stability and degradation pathways based on the forced degradation study and infrared spectroscopy monitoring
• Supporting pre-clinical investigation design for COVID-19 treatments based on the reported in vitro evaluation

Strengths

• First in vitro evaluation of Tenofovir disoproxil fumarate for SARS-CoV-2, as stated in the description
• Includes a forced degradation study that describes a new degradation product

Limitations

• Row count is unknown, which may limit suitability assessment
• Column-level documentation is absent; field semantics must be inferred after download
• Last update date is unknown; freshness unverified

Provenance

Source

Giuliano C. Clososki

Collection Method

Scale-up investigation with in situ infrared spectroscopy monitoring and a forced degradation study, followed by in vitro evaluation for SARS-CoV-2.